drugset
drugset / Trial / NCT00724841

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

NCT00724841 ↗

Phase 1/2 Terminated 1 enrolled Gemin X
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.

Timeline

Start
2008-06
Primary completion
2008-07
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Obatoclax Small molecule 40 mg/m2 Intravenous
Subject Obatoclax Small molecule 50 mg/m2 Intravenous
Subject Obatoclax Small molecule 62 mg/m2 Intravenous
Subject Obatoclax Small molecule 80 mg/m2 Intravenous
Subject Obatoclax Small molecule 100 mg/m2 Intravenous
Subject Obatoclax Small molecule 125 mg/m2 Intravenous
Background Temozolomide Small molecule — Oral

Indications

metastatic melanoma